Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss

Back to Jobs

Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today is presenting data on the

Apply Now